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Background. Cancer patients have highly variable clinical outcomes owing to many factors, among which are genes that
determine the likelihood of invasion and metastasis. This predisposition can be reflected in the gene expression pattern of the
primary tumor, which may predict outcomes and guide the choice of treatment better than other clinical predictors.
Methodology/Principal Findings. We developed an mRNA expression-based model that can predict prognosis/outcomes of
human breast cancer patients regardless of microarray platform and patient group. Our model was developed using genes
differentially expressed in mouse plasma cell tumors growing in vivo versus those growing in vitro. The prediction system was
validated using published data from three cohorts of patients for whom microarray and clinical data had been compiled. The
model stratified patients into four independent survival groups (BEST, GOOD, BAD, and WORST: log-rank test p = 1.761028).
Conclusions. Our model significantly improved the survival prediction over other expression-based models and permitted
recognition of patients with different prognoses within the estrogen receptor-positive group and within a single pathological
tumor class. Basing our predictor on a dataset that originated in a different species and a different cell type may have rendered
it less sensitive to proliferation differences and endowed it with wide applicability. Significance. Prognosis prediction for
patients with breast cancer is currently based on histopathological typing and estrogen receptor positivity. Yet both assays
define groups that are heterogeneous in survival. Gene expression profiling allows subdivision of these groups and
recognition of patients whose tumors are very unlikely to be lethal and those with much grimmer outlooks, which can
augment the predictive power of conventional tumor analysis and aid the clinician in choosing relaxed vs. aggressive therapy.
Citation: Park ES, Lee J-S, Woo HG, Zhan F, Shih JH, et al (2007) Heterologous Tissue Culture Expression Signature Predicts Human Breast Cancer
Prognosis. PLoS ONE 2(1): e145. doi:10.1371/journal.pone.0000145
INTRODUCTION
Cancers are complex tissues whose behavior is strongly influenced
by dynamic interactions between the cancer cells, the tumor’s
stromal cells and the extracellular matrix [1]. Stromal cells provide
growth factors, blood supply, and mechanical support, and
changes in this microenvironment can trigger tissue remodeling,
setting the stage for tumor progression, invasion and metastasis.
Since invasion and metastasis require tumor cells to survive and
grow in sites quite different from the milieu in which they arose,
we reasoned that adaptation of tumor cells to growth in vitro might
require analogous changes in cell physiology, probably mirrored
by changes in gene expression. Thus, we undertook the
comparison of gene expression profiles between mouse plasma
cell tumors (PCTs) growing in mice and PCTs that had been
adapted to growth in tissue culture, hoping to gain insights into the
genes responsible for the adaptation of this particular tumor to
tissue culture conditions. Another goal for this study, which
provides the basis for the present paper, was to determine whether
these data might be extrapolatable to other tumor types and other
species. More particularly, we hypothesized that the alterations in
gene expression required for tumor cells to survive in vitro might be
markers of human cancers that were particularly suited to growth
in distant sites, i.e., more likely to invade or metastasize, two
processes associated with poor prognosis and foreshortened
survival. Specifically, we sought to test whether expression data
from an experimental cancer model in mice, in this case plasma
cell tumors, has the potential of uncovering survival/prognosis
patterns in human cancers by transcending species-specific and
cell lineage-specific gene expression patterns.
Cancer patients have highly variable clinical outcomes based on
many factors including the genetic make-up of the patient, the
genetic and phenotypic variability of the tumors and the way the
tumors interact with their surrounding stroma. It is likely that this
spectrum of clinical courses may also reflect different tumor-
specific genetic predispositions to metastasize and gene expression
heterogeneity that are incompletely recognized by classical
diagnosis methods such as histopathological tumor typing and
staging. This genetic predisposition might be reflected in specific
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patterns of gene expression, and it has long been hoped that
microarray profiling of tumors’ global gene expression could help
identify subgroups of patients that differ in prognosis or in their
response to available therapeutic modalities [2–9]. The ultimate
goal is that gene expression profiles of a new patient’s tumor could
be analyzed in the context of a database of gene expression profiles
from patients with known outcomes. In this way, treatment could
be more precisely tailored to this patient’s expected prognosis and
predicted response to treatment.
We generated a mouse plasma cell tissue culture (PCT-TC)
gene signature by comparing and contrasting the global gene
expression of solid mouse plasma cell tumors with that of plasma
cell tumors adapted to grow in tissue culture. We then used
these signatures in meta-analysis of published reports of human
breast cancer patients that included extensive long-term follow–
up and survival data along with microarray data from these
cancers. We devised three prediction models by which our PCT-
TC signature identified subgroups of patients that could be
stratified by their different survivals. In this way we identified
and validated the existence of four distinct prognostic groups of
breast cancer patients with significant differences in clinical
outcomes. This method is superior to previously published
expression-based survival prediction and may eventually be
useful in predicting prognosis of new patients presenting with
this disease.
RESULTS
Generation of mouse tissue culture signature
For the generation of the PCT-TC signature, microarray-based
global gene expression analysis was performed on 27 individual
RNA samples composed of 17 solid mouse PCTs and 10 tissue
cultured PCT cell lines using Affymetrix U74Av2 microarray
chips. We applied Significance Analysis of Microarrays (SAM) at
the 99 percentile confidence level, and 1162 genes with a 0.001
False Discovery Rate (FDR) emerged as a signature that
characterized the differences in gene expression between these
two groups. Cluster analysis of these SAM-filtered genes
revealed that most solid tumors showed similar expression
patterns and clustered together, while the tissue cultured tumor
cells clustered together, separated from their in vivo growing solid
tumor counterparts regardless of tumor induction protocols
(Fig. 1A). Approximately 70% of these genes showed lower
expression in the cells grown in vitro (indicated in green on the
heat map in Fig. 1A) compared with the solid tumors. Most of
the genes that showed significantly lower expression in cells
growing in vitro encode genes involved in angiogenesis,
chemotaxis, component of extracellular matrix, complement
activation, or cell motility-related genes, while the genes higher
in expression in tissue cultured conditions are genes related to
cell survival (see Table S1). Since these gene families had been
cited in reports analyzing tumor invasion and metastasis [10,11],
tumor-progression processes associated with poor prognosis and
reduced survival; we decided to test this expression signature on
the analysis of human cancer survival based on global gene
expression patterns.
Cross-comparison of gene expression data between
mouse plasma cell tumors with three sets of human
cancer gene expression data
We initially applied our PCT-TC signature to three human
datasets in an attempt to stratify tumor patients into homogeneous
groups that might reflect prognosis. Using only orthologous1
genes that showed significant difference of expression in SAM
analysis of mouse PCT in vivo and in vitro, unsupervised hierarchical
cluster analysis was performed with gene expression data from
patients with mantle cell lymphoma [12], hepato-cellular carcino-
ma [13], and breast cancer [2], independently. Kaplan-Meier
plots and log-rank test for the patients clustering together based on
similarities in gene expression, revealed significantly different
survival estimates in each of these three data sets (Fig. 1B–D).
Thus, the molecular differences that reflect tissue culture
adaptation appeared to be associated with distinct differences in
the clinical outcomes of patients with diverse human cancers.
Construction and validation of prediction models for
human breast cancer patient prognosis
Having demonstrated that our mouse PCT-TC signature can
reflect different prognostic features in human patients with three
different types of cancer, we focused the application of our PCT-
TC expression model to attempt to stratify prognostic subgroups
in the well documented human breast cancer microarray data
from Netherlands Cancer Institute (NKI) [2,3]. Unsupervised
hierarchical cluster analysis of half of these samples (the training
set) using 460 orthologous genes corresponding to our mouse
PCT-TC signature revealed two main clusters (Groups A and B),
and each cluster was composed of three sub-clusters (A1, A2, A3
and B1, B2, B3, Fig. 2A).
Survival analysis of each subgroup by Kaplan-Meier plots with
log-rank test showed significant differences between the two main
clusters (Fig. 2B). The patients in the group with the better
prognosis (Group B) had an overall 85% 10-year survival rate and
a 90.7% 5-year survival rate while the group with poorer prognosis
(Group A) had a 62.3% 10-year survival rate and a 73.8% 5-year
survival rate. The difference was significant with a p value of
0.00245.
Kaplan-Meier plot and log-rank test was also performed using
the 6 different subgroups of patients, three from each of the above-
studied groups A and B. The log-rank test revealed that these six
subgroups also had significant differences in survival, with a p
value of 0.00285 (Fig. 2C). The Kaplan-Meier plot showed the
most dramatic survival differences were between B1 [hereinafter
designated as BEST prognosis subgroup with 96.7% 10-year
survival rate (the overall 5-year survival rate was the same 96.7%)]
and A2 (designated as WORST prognosis subgroup with 53.1% of
survival rate in 10 years and 65.6% in 5 years). The other 4
subgroups exhibited less significant differences and were combined
into a single intermediate subgroup (Fig. 2D). These 3 groups had
very significant differences in survival (p = 0.000233).
This part of the study suggested that our PCT-TC signature
may indeed have the potential to provide a novel prognostic model
that can predict breast cancer patients’ prognosis more precisely
than models published heretofore. To refine this model further
and to sub-stratify the prediction of outcome, we applied 6
different class prediction algorithms [Compound Covariate Pre-
dictor (CCP), Linear Discriminator Analysis (LDA), One Nearest
Neighbor (1NN), Three Nearest Neighbor (3NN), Nearest
Centroid (NC), and Support Vector Machine (SVM)], which
compares two groups at a time, to the NKI microarray data in
1Homologous murine and human genes that have diverged from
each other as a consequence of speciation. Cf., http://www.
informatics.jax.org/userdocs/homology_criteria.shtml
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Figure 1. Mouse plasma cell tumor tissue culture (PCT-TC) signature and survival analysis of human cancer patients
27 RNA samples from 17 solid mouse plasma cell tumors and 10 tissue cultured mouse PCT-TC cell lines (including Baf3, a pre-B cell line) were used
for the generation of PCT-TC signature. A. Mouse plasma cell tumor tissue culture signature. 1162 genes showing significant differences in expression
between solid PCTs and tissue-cultured PCTs were selected by SAM analysis at the 99-percentile confidence level with a 0.001 FDR. B–D. Kaplan-Meier
survival analysis of human cancer patients groups generated by unsupervised cluster analysis with mouse PCT-TC signature. B. Survival analysis of
human mantle cell lymphoma patients group [12] generated by unsupervised cluster analysis with 694 orthologs of the mouse PCT-TC signature
genes. C. Survival analysis of human liver cancer patients [13] generated by unsupervised cluster analysis with 971 orthologs of the mouse PCT-TC
signature genes. D. Survival analysis of human breast cancer patients [2,3,15] generated by unsupervised cluster analysis with 470 orthologs of the
mouse PCT-TC signature genes.
doi:10.1371/journal.pone.0000145.g001
Breast Cancer Prediction
PLoS ONE | www.plosone.org 3 January 2007 | Issue 1 | e145
three independent prediction models for the prediction of
patients subtype as good prognosis vs. bad prognosis (predictor
1), BEST prognosis vs. not BEST (predictor 2), and WORST
prognosis vs. not WORST (predictor 3). All 6 algorithms yielded
very similar results, showing the reliability and robustness of our
approach. However, we felt that including all 6, followed by
vote taking would overcome any weakness in any single
prediction method. Figure 3 presents a schematic overview of this
strategy for the construction of prediction models and evaluation
of outcomes.
Figure 2. Construction of human breast cancer patients’ prognosis prediction models and evaluation of outcomes
A. Unsupervised cluster analysis of NKI training data set (147 samples). It generated two main clusters and six sub-clusters of patients. B. Kaplan-Meier
survival analysis of the two main clusters (Group A and Group B). C. Kaplan-Meier survival analysis of the six subclusters (Group A1–A3 and Group B1–
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The large numbers of human genes in the Agilent microarray that
were most differentially expressed between the three different pairs of
prognostic subtypes (Good vs. Bad, BEST vs. not BEST, and
WORST vs. not WORST) in the training set, were selected
independently (two-sample t-test, p value ,0.001) and applied as
classifiers that estimate the probability of a particular breast cancer
patient belonging to one of these specific subtypes using the above-
mentioned six different types of prediction methods (CCP, LDA,
1NN, 3NN, NC, and SVM) (see Table S2). When applied to
a different group of 148 NKI breast cancer patients as a validation set,
all six prediction methods produced consistent patterns. All Kaplan-
Meier plots in the test set showed significant differences in survival of
patients with specific subtypes when independently analyzed by these
six prediction algorithms (Fig. 4). These results demonstrated not only
a strong association of gene expression pattern with the survival of the
patients, but also a robust reproducibility of these gene expression-
based predictors. It is interesting to note that B3 and B6 in this figure
seem to pick a set of almost perfect survivors, although these BEST
groups are much smaller than that in the other prediction algorithms,
presumably due to stricter selection criteria.
Generation and validation of the four distinct
subgroups of human breast cancer
After we applied these six prediction algorithms to each of the
three class-prediction steps, each patient was assigned to one of
two possible groups at each of the three stages, as follows. If
samples were classified into a particular class three or more times
in the six different prediction methods specified above, it was
assigned to that group; otherwise this patient was assigned to the
other group. Each member of the groups fit satisfactorily onto
similar Kaplan-Meier plots generated with the 6 independent
prediction methods (Fig. 5 A1–A3). When the 147 patients in the
training set were combined with the 148 patients in the validation
set and analyzed in this manner as a single group of 295 patients,
similar results were obtained, indicating the homogenous charac-
ter of the clinical outcomes in the same groups of patients in the
training set and the validation set (Fig. 5 B1–B3).
Based on these three sequential stages of class prediction,
samples were assigned into four independent prognostic subtypes
(BEST, GOOD, BAD, and WORST) as follows. Samples that
were assigned to the Good prognosis group in prediction step 1 but
not assigned to the BEST prognosis group in prediction step 2
[BEST vs. not BEST] were assigned to an intermediate group
designated GOOD. Similarly, samples that did not fall into Good
prognosis group in prediction step 1 (Good vs. Bad) and not
assigned to the WORST prognosis group in prediction step 3
(WORST vs. not WORST) were assigned to an intermediate
group designated BAD. Kaplan-Meier Survival analysis and log-
rank test were performed with these four independent subtypes of
patients (Fig. 5C), and differences among them were visually
Figure 3. Overview of strategy for the construction of prediction models and evaluation of outcomes. Based on the unsupervised cluster analysis
results, 3 independent prediction models are generated.
doi:10.1371/journal.pone.0000145.g003
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apparent. These differences in patient survival were significant
(p = 1.761028) by the log-rank test. These findings strongly
support the view that the four subgroups of human breast cancer
assigned by the PCT-TC signature have distinct patterns of gene
expression. These differences may reflect significant differences in
the mechanism of malignant transformation.
Statistical evaluation of PCT-TC-based prediction
model in human breast cancer
To achieve an independent evaluation of the statistical strength
and the prognostic value of our PCT-TC signature-based
prediction model in human breast cancer, we applied univariate
Figure 4. Kaplan-Meier plots of overall survival with NKI validation set predicted by six different prediction algorithms in 3 independent
prediction models.
A 1–6. Group B (with good prognosis) vs. the rest (Group A, with bad prognosis) (Predictor 1). B 1–6. Subgroup B1 (BEST prognosis) vs. the rest of all
(predictor 2). C 1–6. Subgroup A2 (WORST prognosis) vs. the rest of all (predictor 3). The differences between groups were significant in log rank test,
with p value indicated above each plot.
doi:10.1371/journal.pone.0000145.g004
Breast Cancer Prediction
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Figure 5. Defining four distinct survival subgroups of human breast cancer
A. Predicted outcomes in NKI test set (148 patients). Kaplan-Meier plot for the representative groups for 6 different prediction algorithms. If a sample
was predicted to belong to the test class (black lines) 3 or more times in the 6 different prediction methods, it was assigned to that group. Otherwise
that patient/sample remained in ‘‘rest of all’’ (red lines). There were no 3:3 ties for predictor 1. For predictors 2 and 3, ties were assigned to BEST and
WORST, respectively. B. Predicted outcomes for combined NKI data sets (295 total patients). Kaplan Meier plots of overall survival of two independent
groups identified with two independent analyses (unsupervised clustering in training data set and class prediction in validation set). C. Kaplan-Meier
plot of four independent prognostic subtypes generated with the NKI data set. Four independent prognostic subtypes (BEST, GOOD, BAD, and
WORST) are assigned as follows. Samples that fell into the Group B (good prognosis group) with predictor 1 (Good vs. Bad) but not assigned to the
BEST prognosis group with predictor 2 (BEST vs. all the rest) were assigned to an intermediate group designated GOOD. Similarly, samples that did
not fall into Group B (i.e., those that belonged to Group A, the bad prognosis group) with predictor 1 (Good vs. Bad) but not assigned to the WORST
prognosis group in predictor 3 (WORST vs. all the rest) were assigned to an intermediate group designated BAD.
doi:10.1371/journal.pone.0000145.g005
Breast Cancer Prediction
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and multivariate analysis to commonly accepted clinical and
pathologic risk factors for human breast cancer progression (see
Table S3). The BEST and WORST prognosis predicted groups
showed strong association with overall survival in univariate Cox
proportional hazards analysis. Multivariate analyses that included
all relevant pathological variables, and the predicted subtypes
revealed that BEST prognosis group prediction was significantly
different from the rest of the prognosis groups, independent of ER
status and clinico-pathological features of the tumors. This suggests
that its predictive potential has real clinical utility, and the close
examination of the genes in this signature might also provide better
mechanistic understanding of breast cancer progression.
Comparison of the results from our model of
prognosis prediction with previously defined clinical
index and gene signatures
The predicted prognostic subtypes based on our three-stage class-
prediction method showed strong association with the status of ER
expression, histo-pathological grade [14], 70-gene signature pre-
diction [2,3], core serum-response signature [15,16] and ERBB2
signature [17] but not with age, tumor size, the number of positive
lymph nodes or treatment (Table 1).
Estrogen receptor status and PCT-TC stratification
It is well accepted that ER-positivity is an indicator of good prognosis
in general [5,9], while ER-negativity usually indicates a poor
prognosis, perhaps because these tumors are unlikely to respond to
tamoxifen therapy. Our analysis showed that the ER-negative
patients (N=69) constituted a relatively homogenous group with
a bad prognosis [47 patients (68%) in the WORST prognosis group
and 13 patients (18.8%) in the BAD prognosis group]. On the other
hand the ER-positive patients group (N=226) proved to be much
less homogeneous by our PCT-TC analysis, consisting of mainly 3
subtypes (only 5 patients fell into the WORST group): BEST
prognosis group (69 patients, 30.5%), GOOD prognosis group (106
patients, 46.9%) and BAD prognosis group (46 patients, 20.3%).
When we performed Kaplan-Meier Survival analysis with these sub-
stratified groups of ER-positive patients, our prediction system gave
a significant improvement of prognostic prediction (log-rank test
p= 0.000739) (Fig. 6A). A combined survival analysis of the group of
ER-negative patients with the ER-positive patients that had been
stratified into 3 subtypes by our PCT-TC-based predictor, defined 4
independent subtypes with significant differences in survival
estimates (log-rank test p=5.6461029, Fig. 6B).
Pathologic tumor grading and PCT-TC stratification
In an attempt to improve the prognostic usefulness of histological
grading of breast cancer we combined our predicting system with
classic clinico-pathological phenotypes [18] for the further
stratification of patients, analogous to the approach of Soutiriou
et al., [6]. When we stratified the 101 NKI patients with grade-II
tumors (intermediate malignancy) using our PCT-TC prediction
system, 28 patients were assigned to the BEST prognosis subtype
(Fig. 6C), showing a 96% survival rate (27 out of 28 patients
survived at least 15 years). This indicates that some patients with
very optimistic prognosis can be identified within the patients with
‘‘intermediate’’ grade-II tumors.
Histological tumor-cell type and PCT-TC
stratification
Two very early publications [14,17] used microarray-based global
gene expression analysis to sub-classify breast cancer patients and
defined five different breast cancer ‘‘intrinsic subtypes’’; Luminal
A, Luminal B, ERBB2, Basal, and Normal Breast-like. These
intrinsic subtypes were associated with significant differences in
clinical outcomes. Moreover, it was also reported that those 5
intrinsic-subtypes could also be recognized in a subset of the
patients in the NKI reports (117 tumors from young patients), and
these subclasses were associated with similar clinical outcomes
[19]. When we performed survival analysis of the complete set of
the 295-patient set of NKI samples that had been previously
assigned to one of the 5 intrinsic-subtypes by nearest centroid
classification [19], it confirmed the expected differences in clinical
outcomes (log rank test p = 3.7761027) (Fig. 6D). Applying our
PCT-TC analysis, we achieved an even further stratification of
165 breast cancer patients with the histological types that had been
associated with a bad prognosis, ERBB2-positive, Basal and
Luminal B groups [14,17]. This analysis separated out a group of
patients with a BEST prognosis signature (no deaths in 15 years
for these 11 patients) (Fig. 6E).
In addition, however, the correlation coefficients-based assign-
ment of tumors in the initial publication Sorlie et al. [17]
generated a large number of patients (109 patients from 295
patients) called ‘‘NA’’ (not assigned) even though very low
correlation coefficients cutoff values (,0.1) had been applied.
Re-assignment of the NA samples based on our PCT-TC
prediction system identified 3 subgroups of patients that had
significantly different clinical outcomes (Fig. 6F).
The 70-gene signature and PCT-TC stratification
In the analysis of the NKI data [2,3], a 70-gene signature was
identified that had a very strong predictive power for a two-way
prognosis prediction (good vs. poor). Unfortunately, our analysis
showed that this signature was not as strong in prognosis-
predicting power when applied to an independent data set, such
as that from the Duke University [4] (Fig. S1). One contributor
to this loss of prediction power was the diminished numbers of
predictor genes [only 18 genes (24 probes) of the 70-gene
signature in the Agilent microarray set used for the NKI patients’
samples were present in the Affymetrix microarray used at
Duke].
We attempted a further stratification of these two groups of
patients with our PCT-TC strategy from the NKI data set.
Analysis of the ‘‘poor’’ prognosis group from the 70-gene signature
analysis using our Predictor 2 (BEST vs. not BEST) culled out
a BEST prognosis group [13 patients (8% of the ‘‘bad’’ group)
with only one death in 15 years; Fig. 6G].
Prediction of independent human breast cancer
patients
To further validate our prediction system, we tested our PCT-TC-
derived predictors on two other groups of breast cancer patients
whose survival and microarray expression data have been
published but which utilized different microarray platforms [a
Duke University report, using Affymetrix arrays [4], and
a University of North Carolina (UNC) report, using cDNA
spotted arrays [5]].
Our independent analyses of these two data sets yielded
subgroups with significant differences in survival, similar to our
findings with the NKI patients. The summarized results of 6
different prediction algorithms for the Duke University testing
samples showed patterns similar to the plots for NKI test set of
portraits and showed significance in the log-rank tests for each of
the three predictor stages: (p = 0.0124 for Good prognosis vs. Bad
prognosis, p = 0.0289 for BEST prognosis vs. not BEST, and
Breast Cancer Prediction
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Table 1. Association study of prognosis prediction model with clinical index using the NKI data set.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Predictor 1 (Good vs. Bad) Predictor 2 (BEST vs. rest of all) Predictor 3 (WORST vs. rest of all)
Good N= 184 Bad N= 111 p value BEST N= 70 Rest N= 225 p value WORST N= 52Rest N= 243 p value
Age 0.003606 0.369205 0.268392
,40 yr 28 35 10 53 15 48
40–44 yr 62 23 24 61 10 75
45–49 yr 65 33 24 74 19 79
.= 50 yr 29 20 12 37 8 41
Number of positive nodes 0.622589 0.70623 0.103722
0 91 60 34 117 32 119
1–3 70 36 28 78 12 94
.= 4 23 15 8 30 8 30
Tumor diameter 0.059758 0.195767 0.000928
,= 20 105 50 42 113 16 139
.20 79 61 28 112 36 104
Histologic grade 2.82e-17 2.26e-13 6.73e-12
I 9 66 38 37 3 72
II 79 22 28 73 5 96
III 80 39 4 115 44 75
Mastectomy 0.824198 0.308701 0.338286
No 99 62 34 127 32 129
Yes 85 49 36 98 20 114
Chemotherapy 0.333673 0.692295 0.778588
No 111 74 42 143 34 151
Yes 73 37 28 82 18 92
Hormonal therapy 0.212579 0.109067 0.254934
No 155 100 56 199 48 207
Yes 29 11 14 26 4 36
Estrogen Receptor status 1.70E-21 1.52E-06 2.81E-35
Negative 9 60 1 68 47 22
Positive 175 51 69 157 5 221
NIH Risk assessment 0.00068 0.00237 0.000603
High Risk 141 103 49 195 52 192
Low Risk 43 8 21 30 0 51
70 gene signature 1.20E-18 2.46E-16 5.86E-10
Bad 76 104 13 167 52 128
Good 108 7 57 58 0 115
Core Serum Response signature 5.90E-10 1.72E-17 9.60E-06
1 quartile 65 9 43 31 3 71
2 quartile 51 23 21 53 8 66
3 quartile 42 31 5 68 16 57
4 quartile 26 48 1 73 25 49
ERBB2 correlation 9.32E-20 3.50E-09 2.28E-17
1 quartile 66 8 34 40 0 74
2 quartile 59 15 23 51 2 72
3 quartile 45 28 10 63 13 60
4 quartile 14 60 3 71 37 37
Core Serum Response signature correlation values and ERBB2 signature correlation values are grouped based on quartile (From lowest value to highest values). The
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Figure 6. Prediction of breast cancer patients’ outcomes based on a combination of gene expression and other criteria
The outcome groups previously assigned in the literature based on various criteria (ER status [5,9], pathological tumor grade [6], intrinsic-sub type
[14,17] and 70-gene signature [2,3]) were reassessed and further stratified using our prediction system. A. Kaplan-Meier plot of ER-positive patients
stratified by 3 independent prediction steps. Estrogen receptor-positive patients in the NKI data set were further stratified into the BEST prognosis
group (69 patients, 4 deaths), GOOD prognosis group (106 patients, 23 deaths), BAD prognosis group (46 patients, 17 deaths) and WORST prognosis
groups (5 patients, 1 death). B. Kaplan-Meier plots of survival analysis of ER-negative groups and 3 ER-positive groups that were further stratified by
our 3-step prediction analysis. C. Kaplan-Meier plot for patients with grade II tumors after further stratification with 3 independent prediction steps.
28 patients were assigned to the BEST prognosis subtype, showing a 96% 15-year survival rate (27 out of 28 patients). The 5 patients assigned to the
WORST prognosis subtype had only a 20% (1 of 5 patients) 15-year survival. D. Kaplan-Meier plot for intrinsic-sub type. Survival analysis of the
complete set of NKI samples (295 patients) previously assigned 5 different breast cancer intrinsic-subtypes (Luminal A, Luminal B, ERBB2, Basal, and
Normal Breast-like) by nearest centroid class prediction. E. Kaplan-Meier plot for patients with intrinsic-subtypes associated with bad prognosis (Basal,
ERBB2+, and Luminal B) after further stratification with our 3-step prediction analysis. This predictor revealed 11 patients that fell into the BEST
prognosis group (no deaths within 15 years). F. Kaplan-Meier plot for the cell types that could not be assigned (NA) based on correlation coefficients
cutting threshold of 0.1. Samples previously not assigned (NA) to any of histological cell types were stratified using our prediction system, revealing
subgroups with significantly different clinical outcomes. G. Kaplan-Meier plot for the poor prognosis group in the 70-gene-based prediction after
further stratification with our 3-step prediction analysis.
doi:10.1371/journal.pone.0000145.g006
Breast Cancer Prediction
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p= 0.00245 for WORST prognosis group vs. not WORST) (Fig. 7
A1–A3). Analysis of the UNC data with our prediction system also
stratified the patients showing patterns similar to the NKI data
(p = 0.0109 for Good prognosis vs. Bad prognosis, p = 0.0321 for
BEST prognosis vs. not BEST, and p= 0.0205 for WORST
prognosis group vs. not WORST) (Fig. 7 B1–B3). Combined
analysis of Duke data with UNC data showed outcomes similar to
those revealed in the NKI data set (p = 0.000335 for Good
prognosis vs. Bad prognosis, p = 0.00219 for BEST prognosis vs.
not BEST, and p= 6.2561025 for WORST prognosis group vs.
not WORST) (Fig. 7 C1–C3).
Thus, our method of outcome prediction for two independent
groups of patients provided an accurate and precise estimate of
clinical outcomes that worked on microarray data sets generated
using different microarray platforms and different cohorts of
patients treated at different clinical institutions.
Biological insights into the subtypes of human
breast cancer
A class comparison of the patients in the four different survival
subtypes of the 295 NKI breast cancer patients generated by PCT-
TC stratification by one-way ANOVA analysis provided a list of
the genes that characterized the different prognostic groups. A
total of 3307 genes showed significant differences (p,161028) in
this analysis (Fig. 8A). This list is too long to be included here, but
it included many genes that had been noted in previously reported
analyses of gene expression in human breast cancer. General
agreement between prognosis subtype and clinical predictors, ER
status and histopathological grade can be visually appreciated,
although some important exceptions can be seen. Regardless of
ER status and histological grade, most of the patients’ tumors
within a single subtype showed similar gene expression patterns.
Figure 7. Prediction of independent cohorts of human breast cancer patients
The results are shown as the summarized predicted outcomes determined from the results of 6 different prediction algorithms. A. Kaplan-Meier plots
for the summarized predicted outcomes of Duke University patients [4]. B. Kaplan-Meier plots for the summarized predicted outcomes of UNC
patients [5]. C. Kaplan-Meier plots for the combined predicted outcomes of UNC data and Duke University patients.
doi:10.1371/journal.pone.0000145.g007
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Figure 8. Genes showing significant differences in expression among independent groups (BEST, GOOD, BAD and WORST)
A. Gene clustering of 295 NKI samples using genes selected by one-way ANOVA class comparisons. A total of 3307 genes that showed significant
expression differences (p,161028) in a one-way ANOVA analysis were selected. ER expression status and the histo-pathological grade of each tumor
sample are shown in grey-scale bars beneath the colored BEST – WORST classification bar. The key to the grey-scale designations is found beneath
the heat map. B. PathwayAssistTM–generated figure showing networks of transcription factors activated by EGF and showing significantly higher
expression in tumors from patients in the WORST prognosis group (indicated by red color) compared to the BEST prognosis group. C.
PathwayAssistTM–generated figure showing networks of genes activated by PTGS2 (COX2) and showing significantly lower expression in tumors from
patients in the WORST prognosis group (indicated by green color) compared to the BEST prognosis group.
doi:10.1371/journal.pone.0000145.g008
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Figures 8B and 8C present genetic networks generated by
PathwayAssistTM (Ariadne Genomics) analysis of these expression
data. Figure 8B shows transcription factors most highly expressed
in the WORST subgroup, all of which are activated by EGF. This
finding suggests that continuous, spontaneous stimulation of
EGFR and Her2 signaling may play central roles in particularly
dangerous and metastatic breast cancer tumor types. Figures S2–
S5 depict the large number of genes activated by EGF, IFNG, IL4
and CCNA2 that also show increased expression in the WORST
group of the NKI patients’ tumors, consistent with the previous
notion. Of course, these pathways have considerable cross talk or
overlap in involved genes. Figure S8 is a Venn diagram that
depicts the overlapping genes that are highly expressed in patients
with the WORST prognosis and are involved in the EGF, IL4 and
IFNG pathways. Figures S6 and S7 depict the large number of
genes activated in the WORST group that contribute to the
activation of TNF and AKT. This might explain how the anti-
apoptotic action of AKT signaling is increased in tumors that fall
in the WORST prognosis group and how TNF contributes to the
metastasis of the WORST prognosis group.
Figure 8C depicts genes activated by PTGS2 (COX2) that
shows significantly lower expression in the WORST prognosis
subgroup and higher expression in the BEST subgroup. The
higher expression of IGF1, BCL2, and CCND1 in the BEST
prognosis group (Fig. 8C) was unanticipated, as these genes are
commonly considered to be tumor- promoting genes. The
activation of IGF1, BCL2 and CCND1 by PTGS2 might be the
prolonged legacy of chronic inflammation in early stages of tumor
generation. Following the chronic inflammation stage, genetic or
epigenetic changes leading to altered expression of other cytokines,
growth factors and oncogenes might take over and be responsible
for progression of the tumor.
DISCUSSION
Even though cancers occur in different organs and involve
transformation of many cell types, most cancers share certain basic
differences that separate them from normal cellular counterparts
[20]. Tumors can evade cell death and bypass mechanisms that
normally regulate the cell cycle. Constitutively activated growth
factor receptors provide active proliferation signals in many
tumors [20,21]. Such proliferation-promoting genes commonly
appear in expression signatures of cancer, and sometimes they can
be used to predict clinical outcomes in tumor patients [12,15,16].
However, the common accumulation of proliferation signals has
made it difficult to use these features to generate highly stratified
patient groups with different clinical outcomes and sensitivity to
treatment protocols. Hidden beneath the strong proliferation-
associated genes may be better clues to variable prognosis, e.g.,
proteins associated with the ability of cells to live in foreign sites,
such as those represented in the PCT-TC signature.
A closer examination of the nature of those genes that provided
better stratification of patients may also improve our understand-
ing of the tumorigenic process. In a Gene Ontology (GO) analysis
of this signature (see Table S1), many genes involved in
angiogenesis (GO:0001525), chemotaxis (GO:0006935), as well
as extracellular matrix structural constituents (GO:0005201) and
transmembrane receptor tyrosine kinases (GO:0004714) showed
significant lower expression in tissue culture versions of PCTs.
Most of the genes were previously shown its roles in tumor
metastasis and have provided a basis for different prognostic
outcomes of human cancer patients.
Molecular phenotypying of breast cancer by Perou et al. [14]
delineated four intrinsic-subtypes of breast cancer (Luminal, Basal,
ERBB2+, and Normal Epithelial Group) based on 476 genes that
showed variable expression in 40 breast cancer samples compared
to 20 matched samples that had received doxorubicin treatment.
These molecular phenotypes of breast cancer were shown to be
conserved in independent analysis of different groups of patients,
and they were also associated with significant differences in clinical
outcomes that correlated with the tumor cell types.
Another significant advance in the identification of prognostic
factors using breast cancer microarray expression analysis was the
70-gene signature generated in axillary lymph node-negative
patients by van’t Veer et al. [3]. An extended analysis using the 70-
gene signature applied to an additional 234 patients [2]
documented that this signature-based classification identified
classes of patients with significant differences in clinical outcomes
more consistently and accurately than any clinical index.
However, it is a challenge for even the best prognostic models
when they are tested on different independent patient populations
[22], as most of the model parameters for the signature are
generally optimized for the original data [23–25]. The source of
these difficulties may lie in different sizes of patient cohorts or
different compositions of patient populations, differences in
microarray platforms employed (one dye system vs. two dye
system, etc.), and differences in the way the microarray data were
processed (normalization, scaling, etc.). Nonetheless, if the pre-
dictor used truly reflects basic genetic characteristics relevant to
the mechanisms responsible for the different phenotypes (out-
comes, prognosis and survival), one would expect these combina-
tions of gene expression to be conserved among all groups of
patients with given tumor types. We have shown in detail that our
PCT-TC signature-based outcome-predicting model can out-
perform previous approaches to prognosis prediction for breast
cancer patients, and probably for certain other cancers as well. Just
how widely this approach can be applied will require further
analysis.
Even though genetic signatures may provide the most precise
prognostic prediction for individual tumor patients, it is still not
widely accepted as an essential component in the choice of
therapy. This might be because array-based outcome prediction
has been available for only a short period of time, only small
numbers of patients and samples have been used for its validation,
and because no single approach has emerged with a clear
consensus from the clinical/scientific community.
We think that a possible solution to this acceptance problem is
to apply multi-faceted models for the prediction of prognosis,
which include well-characterized and well-accepted clinical in-
dexes along side newly applied genetic signatures. This approach
should minimize the number of false positives and false negatives
from tumor staging, ER testing and the potentially subjective
interpretation of histo-pathological sections. Adding a microarray
analysis step offers the potential of classifying ‘‘unclassifiable’’
tumors or those designated ‘‘intermediate’’ in character. We have
shown that there is a considerable heterogeneity in ER-positive
populations as well as in patients with grade-II tumors. We feel
that application of PCT-TC predictors could supplement existing
prediction methods and yield more finely tuned, sub-stratified
groups of patients based on molecular genetic similarities. These,
then, could be the basis for the understanding of basic mechanisms
that might be responsible for different clinical outcomes and
provide a means of scientifically predicting prognosis and, if
further developed, susceptibility to treatment protocols.
In summary, we generated a novel prognosis prediction model
for human breast cancer patients based on a mouse plasma cell
tumor tissue culture expression signature. As it is generated based
from a data set that originated in a different animal species and
a different cell type, it may have side-stepped ‘‘over-fitting’’
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problems that often plague models of human cancer patient
prognostic prediction. Testing of our prediction model on 3
independent data sets of human breast cancer patients showed
similar sub-stratification regardless of microarray type and on
patient groups in different clinical institutions.
MATERIALS AND METHODS
Sample Selection and RNA Preparation
A total of 27 samples of RNA were prepared from transplanted
mouse PCT tissues and cell lines derived from them. All solid PCT
samples used for microarray hybridization had been induced in
BALB/c mice by intraperitoneal injections of pristane [26] and
transplanted at least once. Some had been accelerated by injection
of Abelson murine leukemia virus concomitant with the pristane
injection [27]. PCTs were adapted to growth in tissue culture with
difficulty, often requiring cycling through pristane-primed mice
before sustained growth in vitro could be obtained [28]. All tissue
cultured cell lines were maintained in RPMI 1620 medium with
10% fetal bovine serum and 10 ng/ml IL-6. All mice were
maintained in our conventional colony on the NIH campus under
Animal Study Protocol LG-028. Total RNA was prepared from
tissue culture pellets or from frozen tissues pulverized by mortar
and pestle in liquid nitrogen using extraction in TRIzol
(Invitrogen) followed by further purification on RNAeasy columns
(Qiagen).
Microarray Hybridization
Affymetrix U74Av2 microarrays were used for the hybridization of
biotin-labeled cDNA probes synthesized from 5 mg of total RNA
or 1 mg poly(A)+ RNA using Superscript double–strand cDNA
synthesis kit (Invitrogen), Bioarray High Efficiency RNA transcript
labeling kits and Mg-catalyzed fragmentation kit (Enzo) according
to the manufacturers’ instruction. Microarrays were stained with
phycoerythrin-streptavidin (Molecular Probes), scanned with
Affymetrix GeneChip scanner and analyzed with Affymetrix
Microarray Analysis Suite (MAS) version 5.0.
Statistical Analysis of Microarray Data
BRB ArrayTools Version 3.0 (http://linus.nci.nih.gov./BRB-
ArrayTools.html) was used for the analysis of the MAS 5.0 data
set. A log base 2 transformation was applied to the data set before
arrays were normalized. Each array was normalized using median
values of gene expression over the entire array (global normali-
zation). A median array was selected as the reference array for
normalization. Class comparison analysis was performed with
SAM including an estimation of FDR. Cluster analysis was
performed with Cluster and Treeview (http://rana.lbl.gov/
EigenSoftware.htm). For the cluster analysis, the log base 2
transformed data were centered to the mean values of each gene’s
expression.
For the generation of prediction models, samples were divided
into two groups as ‘‘training set’’ and ‘‘validation set’’ in such as
way that each group had a similar composition of follow-up times
since the first diagnosis. Six different prediction methods were
applied for the validation of subclasses: LDA, SVM, NC, 1NN,
3NN and CCP. The numbers of genes in the classifiers were
optimized to minimize misclassification errors by the leave–one-
out cross-validation of the data set. All statistical analyses
were performed in R (version 2.0.1). The probabilities of overall
survival were estimated according to the Kaplan-Meier method.
Significance of difference among subclass was determined by
log-rank test.
Meta-Analysis of Published Data
We worked with several previously published data sets that
combined microarray analysis of gene expression in human cancer
samples with clinical and laboratory data from the patients at time
of tumor discovery and follow-ups and survival analyses of these
patients. Five independent groups published valuable sets of data
that were publicly available and could be used in our analysis.
Mantle cell lymphoma [12] and hepatocellular carcinoma [7]
patients were the first groups studied to compare clinical outcomes
with global gene expression analyses of mouse PCT-TC orthologs.
However, we based most of our studies on the NKI patients in
which Agilent two-color oligo microarrays were used for analysis
of gene expression [2,3], because their total patient number, 295,
and length of follow-up were the greatest. We also performed
meta-analyses on the results generated from 170 breast cancer
patients studied at Duke University using Affymetrix single-color
microarrays for expression analysis [4], and from 96 patients from
the University of North Carolina (UNC) [5] which employed two-
color cDNA microarrays. Both data sets provided valuable
independent test sets against which we could test our approach
for prediction of prognosis. Orthologous genes that were present in
the Affymetrix U74Av.2 mouse microarrays and in the human
microarrays employed in the previously published studies were
selected by using curated mammalian orthology from The Jackson
Laboratory. For the analysis of more than one independent data
set of breast cancer patients (e.g., NKI data sets and the Duke
University data set) each data set was normalized separately and
then combined together. Each set was divided into a training set
and a test set. Before integrating testing data set with training data
set, the expression of each gene was standardized to mean6s.d. of
061 independently in both data sets.
Pathway analysis
Once genes were identified as useful in the stratification of
patients’ outcomes, we attempted to gain insight into molecular
mechanisms that might be involved in generating this hierarchy of
patient outcomes. We employed PathwayAssistTM (version 3.0,
Ariadne Genomics), as an independent pathway analysis tool to
identify connections between differentially expressed genes.





Duke Univ. data: http://data.cgt.duke.edu/oncogene.php
Univ. of North Carolina (UNC) data: https://genome.unc.edu/
SUPPORTING INFORMATION
Figure S1 70-gene signature-based prognosis prediction of Duke
University patients. A. Cluster analysis of patients from Duke
University [4] using the 70-gene signature from the NKI data set
analysis [2]. Note that only 24 probes in the Duke University
Affymetrix microarray platform match the 70 genes from the NKI
Agilent microarray used to define the prognostic predictor in the
NKI data set. B. Kaplan-Meier survival plot of the two main
clusters generated in A.
Found at: doi:10.1371/journal.pone.0000145.s001 (5.38 MB TIF)
Figure S2 PathwayAssistTM-generated figure showing genes that
are activated by EGF and show significantly increased expression
in the tumors from patients in the WORST prognosis group
compared to those in the BEST prognosis group.
Found at: doi:10.1371/journal.pone.0000145.s002 (3.18 MB TIF)
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Figure S3 PathwayAssistTM-generated figure showing genes that
are activated by interferon c and show significantly increased
expression in the tumors from patients in the WORST prognosis
group compared to those in the BEST prognosis group.
Found at: doi:10.1371/journal.pone.0000145.s003 (5.04 MB TIF)
Figure S4 PathwayAssistTM-generated figure showing genes that
are activated by IL-4 and show significantly increased expression
in the tumors from patients in the WORST prognosis group
compared to those in the BEST prognosis group.
Found at: doi:10.1371/journal.pone.0000145.s004 (4.07 MB TIF)
Figure S5 PathwayAssistTM-generated figure showing genes that
are activated by cyclin A2 and show significantly increased
expression in the tumors from patients in the WORST prognosis
group compared to those in the BEST prognosis group.
Found at: doi:10.1371/journal.pone.0000145.s005 (3.58 MB TIF)
Figure S6 PathwayAssistTM-generated figure showing genes that
are activated by tumor necrosis factor and show significantly
increased expression in the tumors from patients in the WORST
prognosis group compared to those in the BEST prognosis group.
Found at: doi:10.1371/journal.pone.0000145.s006 (4.75 MB TIF)
Figure S7 PathwayAssistTM-generated figure showing genes that
are activated by AKT1 and show significantly increased
expression in the tumors from patients in the WORST prognosis
group compared to those in the BEST prognosis group.
Found at: doi:10.1371/journal.pone.0000145.s007 (5.10 MB TIF)
Figure S8 Venn diagram that shows genes activated in common
by EGF, IFN-c or IL-4. EGF expressed a total of 115 genes
significantly more highly in tumors from the patients with the
WORST prognosis group than in patients in the BEST prognosis
group. Of these 115 genes, 26 are also activated by IL-4 and
highly expressed in BEST tumors, and 16 of these are highly
expressed in BEST patients’ tumors and activated by EGF, IL-4
and TNF. The genes activated by more that one of these three
factors are listed in the overlapping sectors.
Found at: doi:10.1371/journal.pone.0000145.s008 (3.27 MB TIF)
Table S1 Functional enrichment analysis of PCT-TC signature
genes. The enrichment of each gene set was estimated by
calculating the cumulated hypergeometric p values of each
biological process provided by Gene Ontology Consortium
(www.gene-ontology.org). Gene annotation according to Gene
Ontology (GO) terms was downloaded from the NCBI (ftp://ftp.
ncbi.nih.gov/gene). In order to obtain representative and
significantly enriched terms, the terms that belonged to a GO
level higher than 2 and that included at least three genes were
considered in our calculation. Statistical significance was de-
termined with a cut-off of p,0.001.
Found at: doi:10.1371/journal.pone.0000145.s009 (0.42 MB
DOC)
Table S2 Summary of the class prediction results for NKI
training set. Genes significantly different between the classes at
0.001 significance level were used for class prediction. 4160 genes
were selected as a classifier for Good vs. Bad group and 1651 genes
were selected as a classifier for BEST prognosis group. For the
prediction of WORST prognosis group 4700 genes were selected
as a classifier. Leave-one-out cross-validation method was used to
compute misclassification rate based on 100 random permuta-
tions.
Found at: doi:10.1371/journal.pone.0000145.s010 (0.05 MB
DOC)
Table S3 Cox univariate and multivariate analysis of risk factors
for death. Parameters showing significance in the Cox pro-
portional hazard model are shown in bold. Age is categorized into
two groups based on .45 years old or not. Lymph node status is
categorized into two groups, one with one or more tumor cells
infiltrated into the lymph node and another group with no tumor
cells infiltrated into the lymph node. P value for statistical
significance was calculated by log-rank test. T1T2 is categorized
based on the diameter of tumor size are .2 cm or not.
Found at: doi:10.1371/journal.pone.0000145.s011 (0.05 MB
DOC)
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